Literature DB >> 7520407

Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).

K Csoka1, R Larsson, B Tholander, E Gerdin, M de la Torre, P Nygren.   

Abstract

The automated fluorometric microculture cytotoxicity assay (FMCA) is based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein diacetate (FDA) to fluorescein by viable cells after a 72-hr culture period in microtiter plates. The FMCA was adopted for chemosensitivity testing of tumor cells from patients with ovarian carcinoma. Thirty-seven samples of solid tumors and malignant effusions were obtained from 35 patients at diagnosis or relapse. Tumor cells from solid samples and effusions were prepared by enzymatic digestion and centrifugation, respectively, followed by Percoll or Ficoll purification. The fluorescence was proportional to the number of cells/well and considerably higher in tumor cells than in contaminating normal cells. The effect of up to 19 cytotoxic drugs was successfully assessed in 70% of the samples and there was a good correlation between drug sensitivity data reported by the FMCA and the DiSC assay performed in parallel. The overall drug sensitivity pattern in vitro corresponded well to the clinical experience. The effect of cisplatin varied considerably between patients and resistance was found also in cases not previously exposed to cytotoxic drugs. The FMCA is a rapid and simple method that seems to report clinically relevant cytotoxic drug sensitivity data in ovarian carcinomas. In the future, this method may contribute to optimizing chemotherapy by assisting in individualized drug selection and new drug development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520407     DOI: 10.1006/gyno.1994.1187

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Authors:  Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Uptake of hyaluronan in hepatic metastases after blocking of liver endothelial cell receptors.

Authors:  H Mahteme; W Graf; B S Larsson; S Gustafson
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

Review 3.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

4.  Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  Daniel Laryea; Anders Isaksson; Colin W Wright; Rolf Larsson; Peter Nygren
Journal:  Invest New Drugs       Date:  2008-10-14       Impact factor: 3.850

5.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

6.  In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

Authors:  Kristina Wiberg; Kristina Carlson; Anna Aleskog; Rolf Larsson; Peter Nygren; Elin Lindhagen
Journal:  Med Oncol       Date:  2008-11-18       Impact factor: 3.064

7.  Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.

Authors:  Elin Lindhagen; Linda Rickardson; Gary Elliott; Lorenzo Leoni; Peter Nygren; Rolf Larsson; Anna Aleskog
Journal:  Invest New Drugs       Date:  2007-04-18       Impact factor: 3.850

8.  Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Authors:  Joachim Gullbo; Elin Lindhagen; Saadia Bashir-Hassan; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Manuel De La Torre; Kristina Luthman; Rolf Larsson
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

9.  Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

Authors:  E Jonsson; H Fridborg; K Csóka; S Dhar; C Sundström; P Nygren; R Larsson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.